Friese K - Search Results

1

Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours.

Lenhard M, Kuemper C, Ditsch N, Diebold J, Stieber P, Friese K, Burges A. Lenhard M, et al. Among authors: friese k. Clin Chem Lab Med. 2007;45(5):657-61. doi: 10.1515/CCLM.2007.120. Clin Chem Lab Med. 2007. PMID: 17484630

2

Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.

Lenhard MS, Nehring S, Nagel D, Mayr D, Kirschenhofer A, Hertlein L, Friese K, Stieber P, Burges A. Lenhard MS, et al. Among authors: friese k. Clin Chem Lab Med. 2009;47(5):537-42. doi: 10.1515/CCLM.2009.134. Clin Chem Lab Med. 2009. PMID: 19317653 Free article.

3

Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers.

Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Rank A, Göhring P, Thaler CJ, Friese K, Bauerfeind I. Toth B, et al. Among authors: friese k. Anticancer Res. 2008 Mar-Apr;28(2A):1107-12. Anticancer Res. 2008. PMID: 18507061 Free article.

4

PET-CT in recurrent ovarian cancer: impact on treatment planning.

Lenhard MS, Burges A, Johnson TR, Stieber P, Kümper C, Ditsch N, Linke R, Friese K. Lenhard MS, et al. Among authors: friese k. Anticancer Res. 2008 Jul-Aug;28(4C):2303-8. Anticancer Res. 2008. PMID: 18751410 Free article.

5

Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort.

Lenhard MS, Mitterer S, Kümper C, Stieber P, Mayr D, Ditsch N, Friese K, Burges A. Lenhard MS, et al. Among authors: friese k. Eur J Obstet Gynecol Reprod Biol. 2009 Aug;145(2):189-94. doi: 10.1016/j.ejogrb.2009.04.031. Epub 2009 May 23. Eur J Obstet Gynecol Reprod Biol. 2009. PMID: 19477060

6

Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer.

Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, Friese K, Jeschke U. Lenhard M, et al. Among authors: friese k. BMC Cancer. 2012 Jan 3;12:2. doi: 10.1186/1471-2407-12-2. BMC Cancer. 2012. PMID: 22214378 Free PMC article.

7

[Uterine leiomyomas: how to proceed].

Fürst S, Lenhard M, Burges A, Friese K. Fürst S, et al. Among authors: friese k. MMW Fortschr Med. 2012 Nov 15;154(20):61-3. doi: 10.1007/s15006-012-1455-7. MMW Fortschr Med. 2012. PMID: 23234123 German. No abstract available.

8

Relapse and survival in early-stage ovarian cancer.

Lenhard SM, Bufe A, Kümper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K, Burges A. Lenhard SM, et al. Among authors: friese k. Arch Gynecol Obstet. 2009 Jul;280(1):71-7. doi: 10.1007/s00404-008-0877-z. Epub 2008 Dec 18. Arch Gynecol Obstet. 2009. PMID: 19093129

9

Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.

Brüning A, Vogel M, Burger P, Rahmeh M, Gingelmaier A, Friese K, Lenhard M, Burges A. Brüning A, et al. Among authors: friese k. Biochem Biophys Res Commun. 2008 Dec 26;377(4):1309-14. doi: 10.1016/j.bbrc.2008.10.167. Epub 2008 Nov 8. Biochem Biophys Res Commun. 2008. PMID: 19000651

10

Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis.

Brüning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, Burges A. Brüning A, et al. Among authors: friese k. Invest New Drugs. 2009 Dec;27(6):543-51. doi: 10.1007/s10637-008-9206-4. Epub 2008 Nov 28. Invest New Drugs. 2009. PMID: 19039521

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

556 results

Search Page